Boehringer Ingelheim Venture Fund

Overview

Established in 2010, the Boehringer Ingelheim Venture Fund (BIVF) is dedicated to investing in groundbreaking biotechnology companies that are at the forefront of therapeutic and digital innovations, aiming to advance biomedical research. The fund focuses on disease-modifying therapeutic concepts and their clinical application, addressing significant medical needs in areas such as oncology, immunology, regenerative medicine, neurodegeneration, infectious diseases, and digital health technologies. BIVF prioritizes the translation of first-in-class concepts that tackle previously undruggable targets. Operating as an evergreen fund with a volume of EUR 350 million, BIVF continually reinvests to fuel its mission. The fund takes an active role with its portfolio companies, delivering significant added value through its extensive drug discovery, scientific, and managerial expertise, along with access to a network of experts within the Boehringer Ingelheim organization. This hands-on approach has established the fund as a valuable partner for entrepreneurs seeking to transform innovative science into meaningful healthcare solutions. With offices in Germany, the United States, and China, BIVF operates with a truly global perspective, identifying promising innovations across major biotech hubs and emerging markets alike. The fund's diverse portfolio spans multiple therapeutic areas, including oncology, immunology, cardiometabolic diseases, respiratory conditions, and central nervous system disorders. Additionally, BIVF invests in digital health technologies, diagnostics, and novel drug delivery platforms that complement Boehringer Ingelheim's core business areas. BIVF's investment strategy includes initial investments ranging from $5-10 million, with the capacity for significant follow-on funding. The investment team consists of experienced life science investors and former biotech executives who provide not only capital but also strategic guidance, industry connections, and operational expertise. This comprehensive support structure enables BIVF to foster long-term partnerships with scientists and entrepreneurs, driving innovation in medical science and improving patient care worldwide.

Investment Focus

• Focus on disease-modifying therapeutic concepts
• Address significant medical needs in specified therapeutic areas
• Translate first-in-class concepts targeting previously undruggable targets
• Operate in major biotech hubs and emerging markets
• Provide strategic guidance, industry connections, and operational expertise
• Foster long-term partnerships with scientists and entrepreneurs
• Invest in digital health technologies, diagnostics, and novel drug delivery platforms
• Align with Boehringer Ingelheim's core business areas